ProQR Therapeutics (PRQR) Competitors $1.99 -0.20 (-9.13%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.50%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. SYRE, SPRY, PRAX, QURE, ATAI, CRON, CRMD, TSHA, IMNM, and AMLXShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), Cronos Group (CRON), CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group CorMedix Taysha Gene Therapies Immunome Amylyx Pharmaceuticals Spyre Therapeutics (NASDAQ:SYRE) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership. Do insiders & institutionals hold more shares of SYRE or PRQR? 80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend SYRE or PRQR? Spyre Therapeutics currently has a consensus price target of $53.40, suggesting a potential upside of 259.84%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 302.01%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is SYRE or PRQR more profitable? Spyre Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -238.52%. ProQR Therapeutics' return on equity of -61.25% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% ProQR Therapeutics -238.52%-61.25%-28.13% Which has more volatility and risk, SYRE or PRQR? Spyre Therapeutics has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Does the media prefer SYRE or PRQR? In the previous week, Spyre Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for ProQR Therapeutics. Spyre Therapeutics' average media sentiment score of 1.07 beat ProQR Therapeutics' score of 1.03 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, SYRE or PRQR? ProQR Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,007.12-$208.02M-$3.40-4.36ProQR Therapeutics$20.46M10.23-$30.04M-$0.46-4.33 SummaryProQR Therapeutics beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$209.37M$3.10B$5.74B$10.24BDividend YieldN/A2.32%5.69%4.59%P/E Ratio-4.3321.3874.9326.41Price / Sales10.23244.04457.2789.16Price / CashN/A44.4425.8129.91Price / Book2.199.6413.256.28Net Income-$30.04M-$53.20M$3.29B$270.38M7 Day Performance-14.59%0.44%0.47%2.70%1 Month Performance-2.93%4.26%4.60%5.99%1 Year Performance7.57%9.43%73.42%25.94% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.6428 of 5 stars$1.99-9.1%$8.00+302.0%+18.4%$209.37M$20.46M-4.33180News CoveragePositive NewsShort Interest ↑SYRESpyre Therapeutics2.2691 of 5 stars$16.63-2.2%$53.40+221.1%-46.7%$1.03B$890K-4.8973News CoveragePositive NewsSPRYARS Pharmaceuticals2.6102 of 5 stars$10.70+6.3%$32.50+203.7%-24.6%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.4726 of 5 stars$40.75-13.0%$85.88+110.7%-37.0%$985.99M$8.55M-3.32110Positive NewsHigh Trading VolumeQUREuniQure3.2159 of 5 stars$17.43-2.9%$37.45+114.9%+191.3%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.8888 of 5 stars$4.52-1.1%$11.25+148.9%+256.2%$979.53M$2.31M-6.5580CRONCronos Group2.4842 of 5 stars$2.48-0.8%N/A+16.1%$957.23M$117.61M49.60450CRMDCorMedix3.9116 of 5 stars$12.75+2.8%$17.33+35.9%+86.2%$925.65M$43.47M17.0030Analyst UpgradeInsider TradeTSHATaysha Gene Therapies2.4684 of 5 stars$3.24-3.6%$8.29+155.7%+34.1%$916.59M$8.33M-9.53180Positive NewsInsider TradeIMNMImmunome2.3272 of 5 stars$9.40-10.6%$22.89+143.5%-42.3%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals2.2108 of 5 stars$10.44+2.4%$12.25+17.3%+344.7%$909.51M$87.37M-4.18200Positive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies Spyre Therapeutics Competitors ARS Pharmaceuticals Competitors Praxis Precision Medicines Competitors uniQure Competitors atai Life Sciences Competitors Cronos Group Competitors CorMedix Competitors Taysha Gene Therapies Competitors Immunome Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRQR Stock Alerts